""

Johnson & Johnson is poised for strong momentum heading into 2026, driven by its diversified portfolio of pharmaceutical, medical device, and consumer products. The company's robust pipeline of new treatments and products is expected to fuel growth, with a focus on areas such as oncology, immunology, and cardiovascular disease. As a global healthcare leader, Johnson & Johnson has a significant presence in over 175 countries, with a workforce of approximately 135,000 employees. The company's commitment to innovation and research and development has resulted in numerous breakthroughs, including recent approvals for several key medications. With a strong track record of delivering consistent financial performance, Johnson & Johnson is well-positioned to capitalize on emerging trends and opportunities in the healthcare sector. As the company looks to 2026, it is expected to continue to invest in strategic areas, including digital health and emerging markets, to drive long-term growth and expansion.